FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200321806> ?p ?o ?g. }

• W4200321806 abstract "Background: Clinical amyopathic dermatomyositis (CADM) represents a subtype of 5-20% of patients with dermatomyositis (DM), which can be categorized into amyopathic dermatomyositis (ADM) and hypomyopathic dermatomyositis (HDM). The characteristics of patients with CADM are still limited in English literature. Objective: To investigate clinical features, cutaneous findings, diagnostic accuracy, and treatment regimen of CADM patients. Methods: Sixty-four patients diagnosed with CADM at Peking Union Medical College Hospital by dermatologists were retrospectively analyzed. Data were recorded in the electronic database at each offline clinical consultation and directly extracted from medical records. 2017 EULAR/ACR criteria for idiopathic inflammatory myositis (IIM) classification was used to identify and classify patients with CADM. Published studies were searched to extract relevant data of CADM patients. Results: This cohort included 38 ADM patients and 26 HDM patients. 2017 EULAR/ACR criteria classified 67.2% of patients with CADM into probable or definite DM. Antimalarials were given to a majority of CADM patients (72.6%, n = 45). However, 68.8% (31 out of 45) required at least one aggressive agent combined with hydroxychloroquine due to insufficient response or side effects. The median of systemic treatments in HDM was significantly higher than ADM (p = 0.007). The number of ADM patients using antimalarials as monotherapy was significantly higher than that of HDM patients (p = 0.031), while the number of HDM patients receiving steroids combined with immunosuppressants was significantly higher (p = 0.025). The median of Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) score improvement was 11.5 and 10.5 for ADM and HDM after a median follow-up of 31.5 and 32.5 months, respectively. Six patients with normal muscle strength developed muscle weakness after a median of 10.5 months (IQR 9-13), and elevated inflammatory markers at initial visit might indicate their muscle weakness development. Conclusions: 32.8% of patients may be overlooked using the three skin variables of 2017 EULAR/ACR criteria. The response rate to single hydroxychloroquine in our cohort was 68.8%. Detailed treatment modalities were different among ADM and HDM. Long-term monitoring for the development of myositis in patients with CADM, especially those with elevated inflammatory markers at initial visit, may be warranted." @default.
• W4200321806 created "2021-12-31" @default.
• W4200321806 creator A5029424597 @default.
• W4200321806 creator A5051000109 @default.
• W4200321806 creator A5077938659 @default.
• W4200321806 date "2021-12-02" @default.
• W4200321806 modified "2023-10-14" @default.
• W4200321806 title "Clinical Characteristics and Management of Patients With Clinical Amyopathic Dermatomyositis: A Retrospective Study of 64 Patients at a Tertiary Dermatology Department" @default.
• W4200321806 cites W1843007555 @default.
• W4200321806 cites W1967590758 @default.
• W4200321806 cites W1992650090 @default.
• W4200321806 cites W2005937602 @default.
• W4200321806 cites W2006326791 @default.
• W4200321806 cites W2031973282 @default.
• W4200321806 cites W2044532917 @default.
• W4200321806 cites W2057103074 @default.
• W4200321806 cites W2057493630 @default.
• W4200321806 cites W2062699039 @default.
• W4200321806 cites W2064439700 @default.
• W4200321806 cites W2070980574 @default.
• W4200321806 cites W2094975067 @default.
• W4200321806 cites W2115404234 @default.
• W4200321806 cites W2131316930 @default.
• W4200321806 cites W2143397985 @default.
• W4200321806 cites W2170143274 @default.
• W4200321806 cites W2195720705 @default.
• W4200321806 cites W2207941088 @default.
• W4200321806 cites W2344270752 @default.
• W4200321806 cites W2365847625 @default.
• W4200321806 cites W2407667348 @default.
• W4200321806 cites W2412516384 @default.
• W4200321806 cites W2419001520 @default.
• W4200321806 cites W2626663410 @default.
• W4200321806 cites W2749448265 @default.
• W4200321806 cites W2750136246 @default.
• W4200321806 cites W2765743865 @default.
• W4200321806 cites W2780702925 @default.
• W4200321806 cites W2782312592 @default.
• W4200321806 cites W2790463973 @default.
• W4200321806 cites W2806261441 @default.
• W4200321806 cites W2886559245 @default.
• W4200321806 cites W2904259347 @default.
• W4200321806 cites W2914534716 @default.
• W4200321806 cites W2923652126 @default.
• W4200321806 cites W2945778715 @default.
• W4200321806 cites W2954814381 @default.
• W4200321806 cites W2982250711 @default.
• W4200321806 cites W2991384167 @default.
• W4200321806 cites W2998485311 @default.
• W4200321806 cites W3006587520 @default.
• W4200321806 cites W3009992138 @default.
• W4200321806 cites W3014858201 @default.
• W4200321806 cites W3109127380 @default.
• W4200321806 cites W3120072801 @default.
• W4200321806 cites W3136812702 @default.
• W4200321806 cites W4211050134 @default.
• W4200321806 cites W4239264503 @default.
• W4200321806 cites W4249265574 @default.
• W4200321806 cites W4293117807 @default.
• W4200321806 cites W3037098539 @default.
• W4200321806 doi "https://doi.org/10.3389/fmed.2021.783416" @default.
• W4200321806 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34926528" @default.
• W4200321806 hasPublicationYear "2021" @default.
• W4200321806 type Work @default.
• W4200321806 citedByCount "3" @default.
• W4200321806 countsByYear W42003218062022 @default.
• W4200321806 crossrefType "journal-article" @default.
• W4200321806 hasAuthorship W4200321806A5029424597 @default.
• W4200321806 hasAuthorship W4200321806A5051000109 @default.
• W4200321806 hasAuthorship W4200321806A5077938659 @default.
• W4200321806 hasBestOaLocation W42003218061 @default.
• W4200321806 hasConcept C126322002 @default.
• W4200321806 hasConcept C16005928 @default.
• W4200321806 hasConcept C167135981 @default.
• W4200321806 hasConcept C195910791 @default.
• W4200321806 hasConcept C2778751314 @default.
• W4200321806 hasConcept C2779123688 @default.
• W4200321806 hasConcept C2779134260 @default.
• W4200321806 hasConcept C2779387793 @default.
• W4200321806 hasConcept C2781232998 @default.
• W4200321806 hasConcept C2781413609 @default.
• W4200321806 hasConcept C3008058167 @default.
• W4200321806 hasConcept C524204448 @default.
• W4200321806 hasConcept C71924100 @default.
• W4200321806 hasConcept C72563966 @default.
• W4200321806 hasConceptScore W4200321806C126322002 @default.
• W4200321806 hasConceptScore W4200321806C16005928 @default.
• W4200321806 hasConceptScore W4200321806C167135981 @default.
• W4200321806 hasConceptScore W4200321806C195910791 @default.
• W4200321806 hasConceptScore W4200321806C2778751314 @default.
• W4200321806 hasConceptScore W4200321806C2779123688 @default.
• W4200321806 hasConceptScore W4200321806C2779134260 @default.
• W4200321806 hasConceptScore W4200321806C2779387793 @default.
• W4200321806 hasConceptScore W4200321806C2781232998 @default.
• W4200321806 hasConceptScore W4200321806C2781413609 @default.
• W4200321806 hasConceptScore W4200321806C3008058167 @default.
• W4200321806 hasConceptScore W4200321806C524204448 @default.
• W4200321806 hasConceptScore W4200321806C71924100 @default.
• W4200321806 hasConceptScore W4200321806C72563966 @default.
• W4200321806 hasFunder F4320327720 @default.

• next